How to reduce the burden of disease and improve prognosis

Type 2 diabetes is known to increase the risk of cardiovascular disease. The ADA guidelines updated in 2025 propose specific screening measures for heart failure, coronary heart disease and PAD. Today, individual active substances from the group of SGLT-2-i and GLP-1-RA are available that have been shown to have cardioprotective effects in certain subpopulations of patients and achieve additive effects through combined use.